[go: up one dir, main page]

SI3221349T1 - Humanizirano tau protitelo pri alzheimerjevi bolezni - Google Patents

Humanizirano tau protitelo pri alzheimerjevi bolezni

Info

Publication number
SI3221349T1
SI3221349T1 SI201531480T SI201531480T SI3221349T1 SI 3221349 T1 SI3221349 T1 SI 3221349T1 SI 201531480 T SI201531480 T SI 201531480T SI 201531480 T SI201531480 T SI 201531480T SI 3221349 T1 SI3221349 T1 SI 3221349T1
Authority
SI
Slovenia
Prior art keywords
alzheimer
disease
tau antibodies
humanized tau
humanized
Prior art date
Application number
SI201531480T
Other languages
English (en)
Inventor
Michal Novak
Eva Kontsekova
Branislav Kovacech
Rostislav Skrabana
Original Assignee
Axon Neuroscience Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axon Neuroscience Se filed Critical Axon Neuroscience Se
Publication of SI3221349T1 publication Critical patent/SI3221349T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7047—Fibrils-Filaments-Plaque formation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
SI201531480T 2014-11-19 2015-11-18 Humanizirano tau protitelo pri alzheimerjevi bolezni SI3221349T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462081809P 2014-11-19 2014-11-19
PCT/IB2015/002610 WO2016079597A1 (en) 2014-11-19 2015-11-18 Humanized tau antibodies in alzheimer's disease
EP15837211.0A EP3221349B1 (en) 2014-11-19 2015-11-18 Humanized tau antibodies in alzheimer's disease

Publications (1)

Publication Number Publication Date
SI3221349T1 true SI3221349T1 (sl) 2021-02-26

Family

ID=55411706

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201531480T SI3221349T1 (sl) 2014-11-19 2015-11-18 Humanizirano tau protitelo pri alzheimerjevi bolezni

Country Status (24)

Country Link
US (3) US10160799B2 (sl)
EP (2) EP3786182A1 (sl)
JP (3) JP6830061B2 (sl)
KR (1) KR20170126855A (sl)
CN (1) CN107428820B (sl)
AU (2) AU2015348012B2 (sl)
BR (1) BR112017010498A2 (sl)
CA (1) CA2966964A1 (sl)
CY (1) CY1123746T1 (sl)
DK (1) DK3221349T3 (sl)
ES (1) ES2848376T3 (sl)
HR (1) HRP20210124T1 (sl)
HU (1) HUE053239T2 (sl)
IL (2) IL251921B (sl)
LT (1) LT3221349T (sl)
MX (2) MX388142B (sl)
PL (1) PL3221349T3 (sl)
PT (1) PT3221349T (sl)
RS (1) RS61431B1 (sl)
RU (2) RU2730668C2 (sl)
SG (1) SG11201703237VA (sl)
SI (1) SI3221349T1 (sl)
SM (1) SMT202100055T1 (sl)
WO (1) WO2016079597A1 (sl)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20152004A1 (es) 2013-03-13 2016-02-07 Prothena Biosciences Ltd Inmunoterapia tau
SG11201703148TA (en) 2014-11-05 2017-05-30 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
SI3221349T1 (sl) * 2014-11-19 2021-02-26 Axon Neuroscience Se Humanizirano tau protitelo pri alzheimerjevi bolezni
US10906964B2 (en) * 2016-05-02 2021-02-02 Prothena Biosciences Limited Antibodies recognizing tau
UA124148C2 (uk) * 2016-05-02 2021-07-28 Протена Біосайенсіс Лімітед Антитіла, що розпізнають тау
WO2017191559A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Tau immunotherapy
AU2018221049A1 (en) * 2017-02-17 2019-09-19 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
EA201992281A1 (ru) * 2017-03-28 2020-02-13 Янссен Вэксинс Энд Превеншн Б.В. Связывающие молекулы, специфично связывающиеся с тау-белком
MX2019013045A (es) 2017-05-02 2020-02-12 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
WO2019023247A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
WO2019048017A1 (en) * 2017-09-07 2019-03-14 Danmarks Tekniske Universitet METHODS FOR REMOVING NOX FROM A GAS STREAM CONTAINING MORE THAN ONE GAS COMPOUND
PE20210115A1 (es) 2017-10-16 2021-01-19 Eisai Randd Man Co Ltd Anticuerpos anti-tau y uso de los mismos
CA3089853A1 (en) 2018-02-01 2019-08-08 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
US12398201B2 (en) 2018-02-19 2025-08-26 New York University Tau single domain antibodies
KR20200144551A (ko) * 2018-03-28 2020-12-29 악손 뉴로사이언스 에스이 알츠하이머병을 검출하고 치료하는 항체-기반 방법
IL278266B2 (en) * 2018-05-03 2025-11-01 Washington University St Louis Methods of diagnosing and treating based on site-specific tau phosphorylation
CA3099306A1 (en) 2018-05-15 2019-11-21 Voyager Therapeutics, Inc. Compositions and methods for the treatment of parkinson's disease
AU2018446059A1 (en) * 2018-10-17 2021-05-20 The University Of Queensland Methods and compositions for treating tauopathies
CN119409813A (zh) * 2018-11-08 2025-02-11 普罗塞纳生物科学有限公司 识别tau的抗体
JP2022523333A (ja) 2019-01-30 2022-04-22 トゥルーバインディング，インコーポレイテッド 抗ｇａｌ３抗体およびその使用
CN113544149B (zh) * 2019-03-03 2024-11-15 普罗塞纳生物科学有限公司 识别tau的抗体
TWI877179B (zh) * 2019-06-27 2025-03-21 德商百靈佳殷格翰國際股份有限公司 抗-angpt2抗體
KR20220062287A (ko) * 2019-08-13 2022-05-16 워싱턴 유니버시티 Mtbr 타우 아이소폼 검출 방법 및 이의 용도
MX2022002852A (es) 2019-09-09 2022-03-25 Axon Neuroscience Se Biomarcadores y tratamientos de la enfermedad de alzheimer y deterioro cognitivo leve.
CA3150369A1 (en) 2019-09-10 2021-03-18 Randall Bateman Blood-based assay for diagnosing and treating based on site-specific tau phosphorylation
EP4073119A1 (en) * 2019-12-12 2022-10-19 Alector LLC Methods of use of anti-cd33 antibodies
WO2021173962A1 (en) * 2020-02-28 2021-09-02 Genemo, Inc. Methods and materials for diagnosis and treatment of neuronal disorder
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
US20230364104A1 (en) * 2020-09-22 2023-11-16 Kathleen E. Clarence-Smith Pharmaceutical combination for the treatment of human hypocholinergic disorders
CN112625129B (zh) * 2020-11-26 2022-05-20 江苏荃信生物医药股份有限公司 一种抗人白介素23及包含其的试剂盒及其检测方法
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
JP2023163821A (ja) * 2022-04-28 2023-11-10 国立大学法人鳥取大学 進行性核上性麻痺の診断マーカー
WO2024036005A1 (en) * 2022-08-10 2024-02-15 Nkmax Co., Ltd. Method of treating alzheimer's disease with expanded natural killer cells
CA3266790A1 (en) 2022-09-15 2024-03-21 Voyager Therapeutics, Inc. TAU PROTEIN BINDING COMPOUNDS
CA3237624A1 (en) * 2023-07-28 2025-04-24 Genentech, Inc. NEW USES FOR OMALIZUMAB
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2026005695A1 (en) * 2024-06-25 2026-01-02 Islam Tohidul Detection of oligomeric tau and soluble tau aggregates

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HU196394B (en) 1986-06-27 1988-11-28 Richter Gedeon Vegyeszet Process for preparing 2-halogenated ergoline derivatives
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
FI102355B1 (fi) 1988-02-11 1998-11-30 Bristol Myers Squibb Co Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjugaattien valmistamiseksi
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
DE69233254T2 (de) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanisierter Heregulin Antikörper
AU3144193A (en) 1991-11-21 1993-06-15 Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
EP0652775B1 (en) 1992-07-27 2000-04-19 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Targeting of liposomes to the blood-brain barrier
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
CA2142190C (fr) 1995-02-14 1998-01-27 Marc Lessard Conduite d'exfiltration d'air use
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
CN102416176A (zh) 1995-07-27 2012-04-18 基因技术股份有限公司 稳定等渗的冻干蛋白质制剂
ES2195036T3 (es) 1995-12-22 2003-12-01 Bristol Myers Squibb Co Conectores de hidrazona ramificados.
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
DK0994728T3 (da) 1997-04-09 2008-12-01 Intellect Neurosciences Inc Rekombinante antistoffer, som er specifikke for beta-amyloide ender, DNA, der koder derfor, samt fremgangsmåder til anvendelse heraf
JP2002512624A (ja) 1997-05-21 2002-04-23 バイオベーション リミテッド 非免疫原性タンパク質の製造方法
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
DK1068241T3 (da) 1998-04-02 2008-02-04 Genentech Inc Antistofvarianter og fragmenter deraf
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
DK2180007T4 (da) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
MX353234B (es) 1999-01-15 2018-01-08 Genentech Inc Variantes de polipeptidos con función efectora alterada.
CA2384006A1 (en) 1999-09-09 2001-03-15 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. A minimal tau peptide for the nucleation of paired helical filaments
DZ3295A1 (fr) 2000-02-24 2001-08-30 Anticorps humanises sequestrant un peptide amyloide .beta.
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
AU2001286930A1 (en) 2000-08-30 2002-03-13 The Board Of Trustees Of The Leland Stanford Junior University Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
US20030083299A1 (en) 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
EP1554572B1 (en) 2001-07-25 2009-10-14 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
WO2003011878A2 (en) 2001-08-03 2003-02-13 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
DE60320258T2 (de) 2002-07-12 2009-06-25 Axon Neuroscience Forschungs- Und Entwicklungs Gmbh Transgenes tier welches das trunkierte alzheimer tau protein exprimiert
PT2357006E (pt) 2002-07-31 2016-01-22 Seattle Genetics Inc Conjugados de fármacos e sua utilização para tratamento do cancro, de uma doença autoimune ou de uma doença infeciosa
CA2507762C (en) 2002-12-03 2013-02-05 Blanchette Rockefeller Neurosciences Institute Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
EP1581203A1 (en) 2002-12-24 2005-10-05 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
JP2007505142A (ja) 2003-09-10 2007-03-08 セダーズ−シナイ メディカル センター 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達
PT1725249E (pt) 2003-11-06 2014-04-10 Seattle Genetics Inc Compostos de monometilvalina capazes de conjugação a ligandos
RU2402548C2 (ru) 2004-05-19 2010-10-27 Медарекс, Инк. Химические линкеры и их конъюгаты
BRPI0516284A (pt) 2004-09-23 2008-09-02 Genentech Inc anticorpo construìdo com cisteìna, método de selecionar anticorpos, compostos conjugados de droga-anticorpo, composição farmacêutica, método para matar ou inibir a proliferação de células de tumor, métodos de inibir a proliferação celular e o crescimento de células de tumor, artigo manufaturado e método para produzir um composto
US8609097B2 (en) * 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
WO2012045882A2 (en) * 2010-10-07 2012-04-12 Ac Immune S.A. Pharmaceutical composition
LT2627672T (lt) 2010-10-11 2018-12-10 Biogen International Neuroscience Gmbh Žmogaus antikūnai prieš tau baltymą
MY183989A (en) 2011-09-19 2021-03-17 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
AU2013243861A1 (en) * 2012-04-05 2014-10-23 Ac Immune S.A. Humanized Tau antibody
EP3792278A3 (en) * 2012-12-21 2021-05-26 Biogen MA Inc. Human anti-tau antibodies
SI3221349T1 (sl) * 2014-11-19 2021-02-26 Axon Neuroscience Se Humanizirano tau protitelo pri alzheimerjevi bolezni

Also Published As

Publication number Publication date
IL251921B (en) 2021-07-29
IL284250A (en) 2021-07-29
RU2017120688A (ru) 2018-12-19
AU2020227007A1 (en) 2020-09-17
PT3221349T (pt) 2021-01-21
JP6864763B2 (ja) 2021-04-28
JP6830061B2 (ja) 2021-02-17
ES2848376T3 (es) 2021-08-09
US20180142007A1 (en) 2018-05-24
AU2020227007B2 (en) 2024-05-30
JP2021119774A (ja) 2021-08-19
US20210009666A1 (en) 2021-01-14
US10160799B2 (en) 2018-12-25
IL251921A0 (en) 2017-06-29
US11319363B2 (en) 2022-05-03
MX2021014367A (es) 2022-01-06
DK3221349T3 (da) 2021-01-04
HRP20210124T1 (hr) 2021-03-19
RU2730668C2 (ru) 2020-08-24
AU2015348012B2 (en) 2020-07-02
RU2017120688A3 (sl) 2019-07-17
WO2016079597A1 (en) 2016-05-26
CN107428820B (zh) 2022-03-22
PL3221349T3 (pl) 2021-05-17
KR20170126855A (ko) 2017-11-20
US10745469B2 (en) 2020-08-18
JP2018502558A (ja) 2018-02-01
HUE053239T2 (hu) 2021-06-28
RU2020126237A (ru) 2020-12-01
EP3221349B1 (en) 2020-11-04
LT3221349T (lt) 2021-02-10
AU2015348012A1 (en) 2017-05-18
CN107428820A (zh) 2017-12-01
WO2016079597A8 (en) 2020-07-02
US20190169276A1 (en) 2019-06-06
SMT202100055T1 (it) 2021-03-15
RS61431B1 (sr) 2021-03-31
MX2017006663A (es) 2017-08-21
HK1244495A1 (en) 2018-08-10
EP3786182A1 (en) 2021-03-03
SG11201703237VA (en) 2017-06-29
JP2020141669A (ja) 2020-09-10
MX388142B (es) 2025-03-19
CY1123746T1 (el) 2022-05-27
BR112017010498A2 (pt) 2017-12-26
CA2966964A1 (en) 2016-05-26
EP3221349A1 (en) 2017-09-27

Similar Documents

Publication Publication Date Title
IL284250A (en) Tau antibodies of human origin in Alzheimer's disease
IL324723A (en) Methods for treating Alzheimer's disease
ZA201900373B (en) Anti-tim-3 antibodies
SG10201601719RA (en) Anti-LAG-3 Antibodies
GB201621439D0 (en) IL-11Ra Antibodies
IL252929A0 (en) Anti-acth antibodies from humans and their use
GB201610044D0 (en) Antibodies
IL251837A0 (en) Anti-endoglin antibodies and their uses
LT3452513T (lt) Humanizuoti anti-il-1r3 antikūnai
PL3311171T3 (pl) Epitop przeciwciała
GB201616699D0 (en) Antibodies
ZA201808317B (en) Anti-tnfrsf25 antibodies
PT3101132T (pt) Anticorpo humano anti-transtirretina
GB201603291D0 (en) Antibodies
GB201512596D0 (en) Biomolecules involved in Alzheimer's disease
PL3180356T3 (pl) Ludzkie przeciwciało anty-fgfr4
IL267271A (en) Antibodies against il-5
PT3484921T (pt) Anticorpos anti-il-22r
SG11201610594WA (en) Anti-il4-il 13 bispecific antibodies
IL260083B1 (en) Antibody against myl9
SG11201703292VA (en) ANTI HUMAN Gas6 MONOCLONAL ANTIBODY
IL272676B (en) Bispecific antibodies against il-4 and il-13
GB201621907D0 (en) Antibody epitope
GB201414038D0 (en) Alzheimer's disease
GB201622197D0 (en) Antibodies